US Stock MarketDetailed Quotes

NKTR Nektar Therapeutics

Watchlist
  • 1.1400
  • +0.0100+0.88%
Close Nov 29 13:00 ET
  • 1.1500
  • +0.0100+0.88%
Post 16:04 ET
210.28MMarket Cap-1357P/E (TTM)

Nektar Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Nektar Therapeutics Q3 2024 Earnings Date

Currency：USDNov 7, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
18.28M
24.12M
+5.84M
Beat Est.
-24.29%
-0.08%
+31.97%
EPS
-0.21
-0.18
+0.03
Beat Est.
+12.13%
+25.00%
+14.61%
Analyst Rating
Buy

Nov 30, 2024

Nektar Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 25.700M--
--2024/Q4-- / 31.390M--
Nov 7, 20242024/Q324.124M / 18.280M--
Aug 8, 20242024/Q223.489M / 17.545M--
May 9, 20242024/Q121.639M / 15.342M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 25.700M--
--2024/Q4-- / 31.390M--
Nov 7, 20242024/Q324.124M / 18.280M--
Aug 8, 20242024/Q223.489M / 17.545M--
May 9, 20242024/Q121.639M / 15.342M--

Unlock Free Earnings Estimates

Nektar Therapeutics Earnings Reports

  • Nektar Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 8 12:20 ET

  • Nektar Therapeutics | 8-K: Nektar Therapeutics Reports Third Quarter 2024 Financial Results

    Nov 7 16:39 ET

  • Nektar Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 9 14:07 ET

  • Nektar Therapeutics | 8-K: Nektar Therapeutics Reports Second Quarter 2024 Financial Results

    Aug 8 16:27 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 30, 2024

    Buy

    • Buy

      66.67%

    • Hold

      33.33%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data